Literature DB >> 21422931

Projections for oesophageal cancer incidence in England to 2033.

Piers Anthony Cheyne Gatenby1, Alison Hainsworth, Christine Caygill, Anthony Watson, Marc Winslet.   

Abstract

The United Kingdom has the highest age-standardized incidence of oesophageal cancer in Europe. This study projects the number of cases of oesophageal cancer arising in England over a 25-year period. Data from National Statistics were used to determine the number and incidence of oesophageal cancers diagnosed during 2001-2007 (separated by age and sex). These data were used with population projections to model the number of cancers that would develop in the future. Variant estimates were undertaken with high/low rates of migration and life expectancy and by varying the rate of change in the incidence of oesophageal cancer. The principal projection showed that, compared with the 2007 baseline, the number of oesophageal cancers in men is predicted to rise by 20% by 2014 and by 40% by 2020. In women, after an initial predicted decline, the number of cancers is predicted to rise above the 2007 baseline by 2012 and to be 5% higher by 2023. The variant projections showed that only a small effect was likely to be caused by changes in net migration (<1% change by 2030) and life expectancy (1% change by 2020). The effect of a 1% increase or decrease in the rate of change of incidence had a more marked effect (10% change by 2017 or 2018). None of the modelled scenarios resulted in an overall decrease in the number of projected cases because of the change in population demographics. The number of cases of oesophageal cancer in England is likely to continue to increase.

Entities:  

Mesh:

Year:  2011        PMID: 21422931     DOI: 10.1097/CEJ.0b013e32834572d2

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

1.  Surgical treatments for esophageal cancers.

Authors:  William H Allum; Luigi Bonavina; Stephen D Cassivi; Miguel A Cuesta; Zhao Ming Dong; Valter Nilton Felix; Edgar Figueredo; Piers A C Gatenby; Leonie Haverkamp; Maksat A Ibraev; Mark J Krasna; René Lambert; Rupert Langer; Michael P N Lewis; Katie S Nason; Kevin Parry; Shaun R Preston; Jelle P Ruurda; Lara W Schaheen; Roger P Tatum; Igor N Turkin; Sylvia van der Horst; Donald L van der Peet; Peter C van der Sluis; Richard van Hillegersberg; Justin C R Wormald; Peter C Wu; Barbara M Zonderhuis
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

2.  Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Authors:  Piers Gatenby; Christine Caygill; Christine Wall; Santanu Bhatacharjee; James Ramus; Anthony Watson; Marc Winslet
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

3.  Projections of cancer prevalence in the United Kingdom, 2010-2040.

Authors:  J Maddams; M Utley; H Møller
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

4.  Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.

Authors:  Piers Gatenby; Santanu Bhattacharjee; Christine Wall; Christine Caygill; Anthony Watson
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

5.  A 25-year trend in gastrointestinal cancers in northern Iran (1991-2016).

Authors:  Hakimeh Mehdizadeh; Ghahraman Mahmoudi; Dariush Moslemi; Ali Bijani; Mohammad Ali Jahani
Journal:  Caspian J Intern Med       Date:  2019
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.